167 related articles for article (PubMed ID: 36505821)
1. PET/CT radiomics for prediction of hyperprogression in metastatic melanoma patients treated with immune checkpoint inhibitors.
Gabryś HS; Basler L; Burgermeister S; Hogan S; Ahmadsei M; Pavic M; Bogowicz M; Vuong D; Tanadini-Lang S; Förster R; Kudura K; Huellner M; Dummer R; Levesque MP; Guckenberger M
Front Oncol; 2022; 12():977822. PubMed ID: 36505821
[TBL] [Abstract][Full Text] [Related]
2. Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibition.
Basler L; Gabryś HS; Hogan SA; Pavic M; Bogowicz M; Vuong D; Tanadini-Lang S; Förster R; Kudura K; Huellner MW; Dummer R; Guckenberger M; Levesque MP
Clin Cancer Res; 2020 Aug; 26(16):4414-4425. PubMed ID: 32253232
[TBL] [Abstract][Full Text] [Related]
3. Noninvasive radiomic biomarkers for predicting pseudoprogression and hyperprogression in patients with non-small cell lung cancer treated with immune checkpoint inhibition.
Li Y; Wang P; Xu J; Shi X; Yin T; Teng F
Oncoimmunology; 2024; 13(1):2312628. PubMed ID: 38343749
[TBL] [Abstract][Full Text] [Related]
4. Imaging Characteristics and Diagnostic Performance of 2-deoxy-2-[
Nakamoto R; C Zaba L; Rosenberg J; Arani Reddy S; W Nobashi T; Ferri V; Davidzon G; Mari Aparici C; Nguyen J; Moradi F; Iagaru A; Lewis Franc B
Mol Imaging Biol; 2021 Feb; 23(1):139-147. PubMed ID: 32789649
[TBL] [Abstract][Full Text] [Related]
5.
Nienhuis PH; Antunes IF; Glaudemans AWJM; Jalving M; Leung D; Noordzij W; Slart RHJA; de Vries EFJ; Hospers GAP
J Nucl Med; 2022 Jun; 63(6):899-905. PubMed ID: 34503964
[TBL] [Abstract][Full Text] [Related]
6. Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria.
Matos I; Martin-Liberal J; García-Ruiz A; Hierro C; Ochoa de Olza M; Viaplana C; Azaro A; Vieito M; Braña I; Mur G; Ros J; Mateos J; Villacampa G; Berché R; Oliveira M; Alsina M; Elez E; Oaknin A; Muñoz-Couselo E; Carles J; Felip E; Rodón J; Tabernero J; Dienstmann R; Perez-Lopez R; Garralda E
Clin Cancer Res; 2020 Apr; 26(8):1846-1855. PubMed ID: 31757877
[TBL] [Abstract][Full Text] [Related]
7. Hyperprogressive Disease (HPD) in Solid Tumours Receiving Immune Checkpoint Inhibitors in a Real-World Setting.
Kanjanapan Y; Guduguntla G; Varikara AK; Szajer J; Yip D; Cockburn J; Fadia M
Technol Cancer Res Treat; 2023; 22():15330338231209129. PubMed ID: 37885403
[No Abstract] [Full Text] [Related]
8. Hyperprogressive Disease in Patients with Non-Small Cell Lung Cancer Treated with Checkpoint Inhibitors: The Role of
Castello A; Rossi S; Mazziotti E; Toschi L; Lopci E
J Nucl Med; 2020 Jun; 61(6):821-826. PubMed ID: 31862803
[TBL] [Abstract][Full Text] [Related]
9. Radiomics of Tumor Heterogeneity in
Ventura D; Schindler P; Masthoff M; Görlich D; Dittmann M; Heindel W; Schäfers M; Lenz G; Wardelmann E; Mohr M; Kies P; Bleckmann A; Roll W; Evers G
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190228
[TBL] [Abstract][Full Text] [Related]
10. Predicting EGFR mutation subtypes in lung adenocarcinoma using
Liu Q; Sun D; Li N; Kim J; Feng D; Huang G; Wang L; Song S
Transl Lung Cancer Res; 2020 Jun; 9(3):549-562. PubMed ID: 32676319
[TBL] [Abstract][Full Text] [Related]
11. CT-Based Peritumoral and Intratumoral Radiomics as Pretreatment Predictors of Atypical Responses to Immune Checkpoint Inhibitor Across Tumor Types: A Preliminary Multicenter Study.
He S; Feng Y; Lin Q; Wang L; Wei L; Tong J; Zhang Y; Liu Y; Ye Z; Guo Y; Yu T; Luo Y
Front Oncol; 2021; 11():729371. PubMed ID: 34733781
[TBL] [Abstract][Full Text] [Related]
12. Proposal for multiple new lesions as complement of hyperprogressive disease in NSCLC patients treated with PD-1/PD-L1 immunotherapy.
Wang M; Huang H; Xu Z; Li Z; Shen L; Yu Y; Lu S
Lung Cancer; 2022 Nov; 173():28-34. PubMed ID: 36116167
[TBL] [Abstract][Full Text] [Related]
13. Multi-lesion radiomics of PET/CT for non-invasive survival stratification and histologic tumor risk profiling in patients with lung adenocarcinoma.
Zhao M; Kluge K; Papp L; Grahovac M; Yang S; Jiang C; Krajnc D; Spielvogel CP; Ecsedi B; Haug A; Wang S; Hacker M; Zhang W; Li X
Eur Radiol; 2022 Oct; 32(10):7056-7067. PubMed ID: 35896836
[TBL] [Abstract][Full Text] [Related]
14. Novel, non-invasive imaging approach to identify patients with advanced non-small cell lung cancer at risk of hyperprogressive disease with immune checkpoint blockade.
Vaidya P; Bera K; Patil PD; Gupta A; Jain P; Alilou M; Khorrami M; Velcheti V; Madabhushi A
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33051342
[TBL] [Abstract][Full Text] [Related]
15. Hyperprogression after immunotherapy.
Abbas W; Rao RR; Popli S
South Asian J Cancer; 2019; 8(4):244-246. PubMed ID: 31807489
[TBL] [Abstract][Full Text] [Related]
16. Analysis of Cross-Combinations of Feature Selection and Machine-Learning Classification Methods Based on [
Gómez OV; Herraiz JL; Udías JM; Haug A; Papp L; Cioni D; Neri E
Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740588
[TBL] [Abstract][Full Text] [Related]
17. Prediction model for hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitors.
Choi YJ; Kim T; Kim EY; Lee SH; Kwon DS; Chang YS
Thorac Cancer; 2020 Oct; 11(10):2793-2803. PubMed ID: 32779394
[TBL] [Abstract][Full Text] [Related]
18. Hyperprogressive disease rarely occurs during checkpoint inhibitor treatment for advanced melanoma.
Schuiveling M; Tonk EHJ; Verheijden RJ; Suijkerbuijk KPM
Cancer Immunol Immunother; 2021 May; 70(5):1491-1496. PubMed ID: 32929554
[TBL] [Abstract][Full Text] [Related]
19. Comparison of 18F-FDG PET/CT Criteria for the Prediction of Therapy Response and Clinical Outcome in Patients With Metastatic Melanoma Treated With Ipilimumab and PD-1 Inhibitors.
Annovazzi A; Vari S; Giannarelli D; Pasqualoni R; Sciuto R; Carpano S; Cognetti F; Ferraresi V
Clin Nucl Med; 2020 Mar; 45(3):187-194. PubMed ID: 31977479
[TBL] [Abstract][Full Text] [Related]
20. Outcome Prediction at Patient Level Derived from Pre-Treatment 18F-FDG PET Due to Machine Learning in Metastatic Melanoma Treated with Anti-PD1 Treatment.
Flaus A; Habouzit V; de Leiris N; Vuillez JP; Leccia MT; Simonson M; Perrot JL; Cachin F; Prevot N
Diagnostics (Basel); 2022 Feb; 12(2):. PubMed ID: 35204479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
